Nuclidium and Guerbet have entered a strategic partnership to advance Nuclidium’s diagnostic and therapeutic copper-based radiopharmaceuticals toward commercialization.
Guerbet has made a strategic, nonexclusive investment in Nuclidium as part of the agreement, which will provide Nuclidium access to Guerbet’s expertise and network in diagnostic imaging, manufacturing, and clinical trials, Nuclidium said. No further details were disclosed.
In addition, François Nicolas, senior vice president of R&D at Guerbet, will join Nuclidium’s board of directors as an observer, the company noted.
